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Purpose: A new syndrome with hypotonia, intellectual disability, and
eye abnormalities (HIDEA) was previously described in a large
consanguineous family. Linkage analysis identified the recessive
disease locus, and genome sequencing yielded three candidate genes
with potentially pathogenic biallelic variants: transketolase (TKT),
transmembrane prolyl 4-hydroxylase (P4HTM), and ubiquitin specific
peptidase 4 (USP4). However, the causative gene remained elusive.
Methods: International collaboration and exome sequencing were
used to identify new patients with HIDEA and biallelic, potentially
pathogenic, P4HTM variants. Segregation analysis was performed
using Sanger sequencing. P4H-TM wild-type and variant constructs
without the transmembrane region were overexpressed in insect
cells and analyzed using sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and western blot.
Results: Five different homozygous or compound heterozygous
pathogenic P4HTM gene variants were identified in six new and six
previously published patients presenting with HIDEA. Hypoventi-
lation, obstructive and central sleep apnea, and dysautonomia were
identified as novel features associated with the phenotype.
Characterization of three of the P4H-TM variants demonstrated
yielding insoluble protein products and, thus, loss-of-function.
Conclusions: Biallelic loss-of-function P4HTM variants were
shown to cause HIDEA syndrome. Our findings enable diagnosis
of the condition, and highlight the importance of assessing the need
for noninvasive ventilatory support in patients.
Genetics inMedicine (2019) 21:2355–2363; https://doi.org/10.1038/s41436-
019-0503-4
Keywords: P4HTM; exome sequencing; HIDEA syndrome;
intellectual disability; hypoventilation
INTRODUCTION
Prolyl 4-hydroxylases (P4Hs) are key enzymes in the synthesis
of collagens and the regulation of oxygen homeostasis.1–3
Previously, variants in the P4HA2 (OMIM 600608) encoding
collagen prolyl 4-hydroxylase (C-P4H) ɑ-2 subunit have been
associated with nonsyndromic high myopia (OMIM
617238),4 and variants in the P4HB (OMIM 176790)
encoding prolyl 4-hydroxylase β-subunit have been associated
with Cole–Carpenter syndrome (OMIM 112240),5 while
variants in the EGLN1 (OMIM 606425) coding for a
hypoxia-inducible factor (HIF) isoenzyme HIF-P4H/PHD2
have been associated with familial erythrocytosis and high
altitude adaptation hemoglobin.6–9 A transmembrane prolyl
4-hydroxylase (P4H-TM) is encoded by the P4HTM gene
(OMIM 614584), which has not yet been unequivocally linked
to any Mendelian disorder. P4H-TM has its highest
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expression in the brain and eye,10,11 and it participates in the
oxygen-dependent regulation of the hypoxia-inducible factor
(HIF). The normal functioning of P4H-TM has been assessed
to be crucial for normal vision and renal function in mice.12
However, the relevance of P4H-TM to human disease remains
to be clarified.
In a previous study, we identified a large Finnish family
with multiple affected family members presenting with a
syndromic form of severe cognitive impairment.13 All the
affected individuals had profound intellectual disability,
hypotonia, and strabismus; we proposed the acronym HIDEA
(hypotonia, intellectual disability, and eye abnormalities) for
this condition. Our study identified a recessive disease locus
in the chromosomal region 3p22.1-3p21.1. However, because
all affected individuals carried potentially pathogenic biallelic
variants in three genes, P4HTM, TKT, and USP4, segregating
with the disease, the causative gene remained elusive.
In the current study, we report seven novel patients from
four unrelated families presenting with HIDEA. DNA was
available from six patients who carried potentially pathogenic
biallelic P4HTM gene variants. One of the patients carried the
same previously published homozygous potentially patho-
genic variants in P4HTM, TKT, and USP4 genes. Five of the
patients had novel homozygous or compound heterozygous
variants only in the P4HTM gene, thereby indicating that
P4HTM is the causative gene. Variant characterization
demonstrated that the variants yield an insoluble protein
product. In summary, we present robust evidence that
HIDEA is caused by biallelic pathogenic P4HTM gene
variants, and delineate the clinical characteristics of this
syndrome.
MATERIALS AND METHODS
We conducted clinical and molecular genetic studies on seven
patients from four families presenting with the phenotype
resembling previously described patients with HIDEA
syndrome.13 Patients were enrolled in the study from four
centers (Clinic for Children and Adolescents, Oulu University
Hospital, Oulu, Finland; Texas Children’s Hospital, Houston,
TX; Kaiser Franz Josef Hospital with G.v. Preyer Children’s
Hospital, Vienna, Austria; Department of Clinical Genetics,
Amsterdam UMC, University of Amsterdam, Amsterdam,
The Netherlands). Novel patients were recruited in the study
based on the clinical phenotypes and biallelic potentially
pathogenic P4HTM variants in patients resembling patients
with HIDEA syndrome previously described by Kaasinen
et al., which allowed clinicians and relatives of patients with
HIDEA syndrome and biallelic potentially pathogenic
P4HTM variants to contact the corresponding author
(L.A.).13 Furthermore, we re-evaluated the patients of the
previously published study.13 Written informed consent was
obtained from all the parents or guardians of the patients
participating in this study, including permission to publish
photos. The study was approved by the ethics committees of
the Northern Ostrobothnia Hospital District at the Oulu
University Hospital and Baylor College (Houston, TX) (for
family 2).
Molecular genetic studies
We extracted genomic DNA from peripheral blood or buccal
swab samples of the probands, their affected siblings, and
their parents using standard methods. We performed exome
sequencing (ES) at the Broad Institute of MIT and Harvard
(Cambridge, MA) for family 1; at the Baylor Genetics
Laboratory (Houston, TX) for family 2; at the Neuromuscular
Research Department, Medical University of Vienna, Austria,
for family 3; and at the Department of Clinical Genetics,
Amsterdam UMC, University of Amsterdam, Amsterdam,
The Netherlands, for family 4. Segregation of P4HTM variants
within the families was confirmed by Sanger sequencing.
More details on ES analyses are provided in the Supplemen-
tary Note including detailed clinical data.
Characterization of P4H-TM variants
Fibroblasts and myoblasts from healthy control individuals
were cultured, RNA was isolated, and reverse transcription
polymerase chain reaction (RT-PCR) was performed to
identify the transcript variants for P4H-TM, as described in
the Supplementary Note.
P4H-TM variants were generated to the pVL1392–P4H-
TM88–502 construct10 using routine PCR with appropriate
primers (available on request). To generate the baculoviruses,
variant constructs were transfected into Sf9 cells in the
presence of flashBAC DNA with baculoFECTIN II transfec-
tion reagent (Oxford Expression Technologies) according to
the flashBAC transfection protocol. Transfection of the wild-
type construct has been described previously.10 Baculovirus
stocks were amplified twice, and the amplified virus stocks
were used to infect Sf9 cells grown as adherent culture on 10-
cm tissue culture plates in complete TNM-FH insect cell
media (Sigma-Aldrich). Cells were harvested 72 hours after
infection, washed with phosphate buffer saline (PBS), and
stored at -80 °C until use.
For lysis, the cells were thawed, resuspended, and homo-
genized in 5 ml lysis buffer containing 10 mM Tris-HCl pH
7.8, 100 mM glycine, 150 mM NaCl, 20 mM imidazol, 2 mM
CaCl2, 20 µM FeSO4, 0,1% Triton X-100, and 1X Complete
EDTA-free protease inhibitor (Roche). The insoluble and
soluble fractions were separated with a 15-minute centrifuga-
tion at 20,000 × g at 4 °C. Cell pellets were washed twice with
5 ml lysis buffer and centrifuged again after each wash. The
supernatants with soluble fractions were pooled together.
Finally, the cell pellet was resuspended in 5 ml of lysis buffer,
and sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis (SDS-PAGE) samples were prepared of the insoluble and
soluble fractions. Two 10% SDS-PAGE gels were run parallel
to each other and a threefold excess of the soluble sample
versus the insoluble sample was loaded to take into account
the increased volume from the washes. Further, one of the gels
was stained with Coomassie, while the other was transferred
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overnight (4 °C, 30 V) to a polyvinylidene difluoride (PVDF)
membrane. The membrane was blocked, incubated for two
hours (4 °C) with 1:10,000 dilution of rabbit anti-P4H-TM
antibody,10 and for one hour (4 °C) with 1:5000 dilution of
HRP-conjugated goat antirabbit antibody (Dako Denmark
A/S, Glostrup, Denmark). Finally, the membrane was
incubated for one minute with Pierce ECL Western Blotting
Substrate (Thermo Scientific) and for three minutes with
Amersham Hyperfilm ECL (GE Healthcare).
Analyses of skeletal muscle biopsy and autopsy samples
As a part of clinical diagnostics, skeletal muscle biopsy
samples had previously been taken from 3 of 13 patients due
to suggested neurometabolic disease. Histology and histo-
chemistry on skeletal muscle samples (patients 1, 2, and 5)
and autopsy tissue samples (patient 13) were performed
using standard methods. Further, the activities of mitochon-
drial respiratory chain enzyme complexes were determined
from skeletal muscle biopsy samples, as described
previously.14
RESULTS
Clinical delineation of the patients with P4HTM variants
Clinical findings of patients 1–7 compared with an update of
the previously described patients13 are compiled in Table 1.
Eight patients are currently alive (current age between 3 and
55 years), and five are deceased (age at death between
7 months and 61 years). Nine patients are male, and four are
female. All the patients have hypotonia (N= 13/13), and
either intellectual disability (N= 12/13) or developmental
delay (1/13, patient 4 who died at the age of 7 months).
Furthermore, the common presenting features include
strabismus (N= 11/13, 85%), epilepsy (N= 10/13, 77%),
and central or obstructive sleep apnea (N= 8/13, 62%). Nine
patients have a medical history of pneumonia or recurrent
pneumonias (N= 9/13, 69%). Four patients have had
respiratory distress and required respiratory support during
pneumonias, and three patients died during pneumonia or
other respiratory tract infections. Some patients also show
dysautonomia, including constipation (N= 6/13, 46%),
recurrent hypothermia or hyperthermia (N= 4/13, 31%),
and reduced sweating (N= 2/13, 15%). Further, some patients
have suspected recurrent parasomnias (N= 4/13, 31%). Six
patients (N= 6/13, 46%) have a body mass index (BMI) over
25 kg/m2. Two patients (N= 2/4, 50%) had advanced bone
age at the age of 8 years. Brain magnetic resonance image
(MRI) is normal in most patients.
Detailed clinical descriptions of the patients are provided
in the Supplementary Note. The characteristic gait of
patients 2, 3, 8, 10, and 11 is demonstrated in Supplementary
Videos 1-5.
Histopathological and biochemical findings of skeletal
muscle samples and brain autopsy sample
The muscle biopsy of patient 1 showed low activity of
mitochondrial respiratory chain complex III. In addition, the
muscle biopsy of patient 2 was suggestive of a mitochondrial,
neurometabolic disease. Electron microscopy indicated
increased mitochondria, with some that were enlarged and
abnormally shaped. Mitochondrial respiratory chain activities
revealed a decrease in complexes I–IV. Furthermore, the
muscle biopsy of patient 5 showed an increased variability of
muscle fiber diameters, hypertrophied muscle fibers, scattered
small atrophied fibers, and basophilic muscle fibers (Supple-
mentary Fig. 1). The muscle biopsy sample of patient 13,
taken during autopsy, showed unspecific type 2 muscle fiber
atrophy (Supplementary Fig. 2A) and COX-negative fibers
suggestive of mitochondrial pathology. In addition to these
findings in skeletal muscle samples, two patients (patients 1
and 13) had mild fatty degeneration of liver. Patient 13’s
autopsy also revealed that the cerebellum was atrophic, and
histologically there was both loss and degeneration of
Purkinje cells (Supplementary Fig. 2B).
Analysis of the P4HTM gene
All seven Finnish patients (family 1, patient 1 and family 5,
patients 8–13) had a homozygous P4HTM gene variant
c.1073G>A (NM_177938.2, GRCh38 g.3:49005046G>A,
rs182812551). While this variant is predicted to cause a
missense change in the canonical transcript, which was not
expressed in fibroblasts and myoblasts, it creates an in-
frame loss of complete exon 6 of the main transcript
(NM_177939.2) on the RNA level (r.888_1073del).13 The
parents of the patients were heterozygous carriers of the
variant. The variant is present in the Genome Aggregation
Database (gnomAD, http://gnomad.broadinstitute.org/
variant/3-49042479-G-A) database with a minor allele
frequency (MAF) of 9.75 × 10−5; the allele frequency is
20× higher in Finland (7.8 × 10−4) than in non-Finnish
Europeans (4 × 10−5), and there are no homozygous
individuals.
Two brothers of family 2, patients 2 and 3, were compound
heterozygous for the P4HTM gene c.482A>C; p.(His161Pro)
(NM_177938.2, GRCh38 g.3:49001483A>C) and c.286dupC;
p.(Gln96Profs*29) (NM_177938.2, GRCh38 g.3:48990542dupC)
variants. The father was a heterozygous carrier of the P4HTM
gene c.286dupC; p.(Gln96Profs*29) variant and the mother was
a heterozygous carrier of the P4HTM gene c.482A>C;
p.(His161Pro) variant. The healthy sister was heterozygous for
the P4HTM gene c.482A>C; p.(His161Pro) variant and negative
for the c.286dupC; p.(Gln96Profs*29) variant.
Two brothers of family 3, patients 5 and 6, were
homozygous for the c.1594C>T; p.(Gln532*) (NM_177938.2,
GRCh38 g.3:49006809C>T) variant. Their parents were
heterozygous carriers. No DNA was available from patient
4, who presented with a similar clinical phenotype as his
affected siblings.
Trio ES analysis of patient 7 (family 4) and his parents
revealed that the patient had a homozygous variant in the
P4HTM gene c.949delG (NM_177938.2, GRCh38
g.3:49004922delG). The parents carried this variant in a
heterozygous state. This deletion predicts a frameshift change
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in the protein. Valine at position 317 is the first affected
amino acid, with a premature stop codon after 28 amino acids
p.(Val317Phefs*30). Frameshift variants creating a premature
stop codon yield a shorter protein or no protein at all.
The pedigrees, identified variants, and their location in the
protein are illustrated in Fig. 1. The genetic findings are
described in Supplementary Table 1.
Characterization of the variants
Previously, we characterized in vitro recombinant P4H-
TM88–502 of the 502-residue noncanonical isoform, which
lacks the transmembrane domain expressed in insect cells.10
Our RT-PCR analyses suggested that the 502-residue variant
is the major transcript expressed from human-derived cells
(Supplementary Fig. 3); therefore, we used it here to
separately generate the variants corresponding to p.His161-
Pro, p.Gln532* and p.Arg296Ser;Val297_Arg358del on this
backbone and expressed these variants in insect cells along
with wild-type P4H-TM88-502. All variants yielded a recombi-
nant enzyme analyzed using SDS-PAGE and Coomassie blue
or western blotting (Fig. 2). However, the fraction of soluble
protein was severely reduced for the p.Gln532* variant and
completely abolished for the p.His161Pro and p.Arg296Ser;
Val297_Arg358del variants (Fig. 2). Despite the lack of the C-
terminal endoplasmic reticulum retention signal Arg-Val-
Glu-Leu in the p.Gln532* variant, we were unable to detect it
in the expression medium at the end of the 72-hour
expression period (data not shown). The P4HTM variants
studied here reside in different parts of the polypeptide and
represent different types of variants. Despite these differences,
the outcome is very similar. Although no structural data is
available on P4H-TM, the insolubility of the variants suggests
improper folding of the proteins. Together, these data suggest
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1 2 3 1 2 3 1 12 23 4
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II II II II
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Fig. 1 Pedigrees and Sanger validation and segregation of the identified P4HTM variants. (a) The segregation of the P4HTM c.1073G>A variant
(NM_177938.2) in family 1. The protein defect of the biologically active main transcript is given in parenthesis (NM_177939.2). (b) The segregation of the
compound heterozygous P4HTM c.286dupC; p.(Gln96Profs*29) and c.482A>C; p.(His161Pro) variants (NM_177938.2) in family 2. (c) The segregation of
the P4HTM c.1594C>T; p.(Gln532*) variant (NM_177938.2) in family 3. (d) The segregation of the P4HTM c.949delG; p.(Val317Phefs*30) variant
(NM_177938.2) in family 4. (e) Facial figure of patient 1 (F1:II.3) shows facial hypotonia with tented upper lip vermilion and open mouth posture, a round
face, and strabismus. (f) Facial figure of patient 2 (F2:II.1) shows hypotonic/myopathic facial appearance with a tented upper lip vermilion and open mouth
posture. (g) Facial figure of patient 3 (F2:II.3) shows marked facial hypotonia with open mouth posture, giving a myopathic facial appearance. (h) Depiction
of the P4HTM protein and location of the variants identified in the four families.
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Fig. 2 P4H-TM wild-type (WT) and variant enzymes were over-
expressed in insect cells and analyzed with sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and western
blotting. Cells were lysed and the proteins were separated into insoluble
(IS) and soluble (S) fractions. Both fractions of WT and variant enzymes p.
His161Pro, p.Gln532*, and p.Arg296Ser;Val297_Arg358del (Ex6del) were
loaded on 10% SDS-PAGE, and the gels were either stained with Coo-
massie blue (top) or western blotting against P4H-TM (bottom).
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that the variants identified in the patients cause loss of
function of P4H-TM.
DISCUSSION
In this study, we report seven new patients from four
unrelated families and a clinical update of a large previously
published consanguineous family with HIDEA syndrome
caused by biallelic P4HTM variants. The phenotype is
characterized by muscular and central hypotonia, hypoventi-
lation, intellectual disability, dysautonomia, epilepsy, and eye
abnormalities (HIDEA). Variant characterization demon-
strates that the variants affect protein folding by yielding an
insoluble protein product.
P4H-TM has a broad expression pattern, with the highest
expression levels in the brain and eye. All the patients with
P4HTM gene variants have developmental delay or intellec-
tual disability and visual abnormalities—such as strabismus,
rotating eye movements, nystagmus, or cortical blindness—
thereby suggesting that P4H-TM is crucial for the functioning
of the normal human brain as well as the visual tract. Muscle
biopsy samples from four patients demonstrate increased
variability of the muscle fiber diameters, mild type 2 muscle
fiber atrophy and COX-negative fibers, and decreased
mitochondrial respiratory chain enzyme activities in two
patients, thereby suggesting that a defect in P4H-TM may also
disrupt normal mitochondrial function. The autopsy of a 61-
year-old patient with the homozygous c.1073G>A variant
revealed loss and degeneration of Purkinje cells, which could
be caused by a long-term undiagnosed hypoventilation and/or
neurodegeneration based on progressive neurodegenerative
diseases.
P4H-TM knockout mice reveal overlapping phenotypic
features with HIDEA patients with biallelic P4HTM variants,
such as retinal defects causing vision impairment,12 thereby
suggesting that loss-of-function is the possible underlying
mechanism. Further, mouse studies suggest that P4H-TM is
necessary for normal visual and renal function.12 As
mentioned above, the patients exhibit various visual abnorm-
alities, such as congenital nystagmus, strabismus, rotating eye
movements, achromic retinal fundi, and cortical blindness.
However, patients with P4HTM gene variants did not
show any evidence of structural kidney abnormalities or
albuminuria indicative of decreased kidney function, even at
an older age.
In addition to the previously described combination of
symptoms, this study reveals hypoventilation, including
obstructive and central sleep apnea, dysautonomia, and an
increased tendency to develop respiratory distress during
pneumonias as novel characteristic clinical features of
HIDEA patients. Several patients have BiPAP dependency
at night due to central and obstructive sleep apnea or
hypoventilation especially during respiratory infections
requiring respiratory support. Four patients (4/13, 31%)
had infantile onset tendency to respiratory insufficiency and
respiratory arrest resulting in infantile or childhood death of
three of them. There is heterogeneity in the clinical
presentation of patients even with exactly the same
pathogenic biallelic P4HTM variants suggesting that the
disease severity is modified by additional genetic and
environmental factors.
Further, we found that the P4HTM c.1073G>A variant
creates an in-frame loss of exon 6 from the messenger RNA
(mRNA) of the 502-residue transcript variant 1
(NM_177939.2), which yields an insoluble protein product.
This is consistent with the latest research findings that
pathogenic variants altering protein code often disrupt
splicing.15 Interestingly, the noncanonical transcript
(NM_177939.2) coding for the 502-residue protein was the
prevalent transcript variant expressed in normal human fibro-
and myoblasts instead of the canonical transcript
(NM_177938.2) yielding a 563-residue protein. Theoretically,
the canonical transcript coding for the 563-residue protein
could be expressed in brain tissue, which is critical for HIDEA
syndrome, but we do not have any experimental evidence to
prove this. In northern blot analysis in brain the major
P4HTM mRNA species was 2.3 kb, unlike in all other tissue
studied, where it was 1.8 kb,10 which may indicate that in the
brain the canonical transcript is expressed. Both transcripts
have nine exons, but the transcript coding for the 502-residue
protein excludes parts of exons 6 and 7. All the pathogenic
variants identified in this study located in areas of the P4HTM
sequence present in both transcripts, and it is currently
unknown whether HIDEA syndrome could be caused by
biallelic pathogenic variants located in parts of exons 6 or 7
that are not present in the transcript coding for the 502-
residue protein.
P4H-TM was originally suggested to be a fourth HIF-
P4H,16 although it was later reported to be more closely
homologous to the C-P4Hs.10 Unlike neither of the previously
characterized P4Hs, it has an N-terminal EF-hand motif16
that is implicated in calcium binding. Recombinant P4H-TM
did not hydroxylate in vitro type I collagen polypeptide but it
hydroxylated HIF1α.10 Its downregulation by small interfer-
ing (siRNA) stabilized HIFα,10 and its genetic knockout in
mice associated with induction of renal erythropoietin
expression similarly to inhibition of HIF-P4Hs.17 In cortical
neurons genetic deficiency of P4H-TM stabilized HIF1α
under normoxia, and in tissues with high endogenous P4H-
TM expression level, such as brain, eye, and kidney, the
expression of certain HIF target genes was more upregulated
in hypoxia compared with wild-type mice.12 However, its
location having the catalytic domain within the endoplasmic
reticulum lumen, and its ability to also hydroxylate to a low
extent HIFα polypeptide, where the HIF-P4H prolines were
mutated to alanines, would suggest it may have other
substrates than HIFα.10 The only known genetic variants of
any HIF-P4H are those for HIF-P4H-2, the most abundant
isoenzyme whose inhibition alone stabilizes HIFα3 that
associate with erythropoiesis. As these variants did not cause
a complete loss-of-function, and some even had a gain-of-
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function phenotype, it may be that complete loss of HIF-P4H-
2 catalytic activity, which would result in a full-powered HIF
response, is not tolerable in humans, similarly to mice.18
Therefore direct comparison of the phenotype of the loss-of-
function P4HTM variants characterized here to regulation of
the hypoxia response is not feasible.
Autosomal recessive inheritance is estimated to have a
small contribution in the etiology of intellectual disability in
outbred populations.19 Northern Finland is a known genetic
isolate, where the current population has arisen from a
small number of founder families, and enrichment of rare
recessive gene variants has been demonstrated in this young
population.20 All the Finnish patients in this study had the
same variant in the P4HTM, thereby suggesting a founder
effect.21 Homogeneous populations, such as the Finnish
population, that share long segments of linkage disequili-
brium are useful in mapping the causative locus of a
monogenic disease; however, the homogeneous genetic
background hinders the identification of the actual
disease-causing gene as multiple variants in different genes
in the same locus may cosegregate with the disease. In
contrast, heterogeneous populations with marked genetic
variability facilitate in underpinning the causative gene and
broaden the knowledge of the full phenotypic spectrum
caused by a specific gene. Studying patients with the same
monogenic syndrome from different ethnic backgrounds
has repeatedly revealed novel disease-causing genes. Inter-
national collaborations may enable the identification of the
causative gene and the delineation of the phenotype even in
very rare childhood heritable diseases.22
In conclusion, we report seven new patients with the
HIDEA syndrome and demonstrate that the phenotype in
this cohort of patients is strikingly similar to the previously
studied patients with the syndrome. Genetic analysis
identified recessively inherited intragenic P4HTM variants
as an underlying cause of the syndrome. Variant character-
ization suggested that the identified variants cause loss of
function of P4H-TM. Novel, previously undescribed fea-
tures include hypoventilation (most pronounced during
respiratory infections), central and obstructive sleep apnea,
and dysautonomia. This indicates the importance of
performing polysomnography in patients with biallelic
pathogenic P4HTM variants and assessing the possible
need for noninvasive ventilatory support to prevent sudden
death. Our results demonstrate that biallelic loss-of-
function P4HTM gene variants cause HIDEA, and greatly
facilitate the diagnosis and management of this challenging
condition.
SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436-
019-0503-4) contains supplementary material, which is available
to authorized users.
ACKNOWLEDGEMENTS
We thank all the families that participated in this study. Further,
we acknowledge Pirjo Keränen, BCO sequencing core, for
excellent technical assistance. This study was supported by the
Academy of Finland Grants 266719 and 308009, the S. Jusélius
Foundation, the Emil Aaltonen Foundation, and the Jane and
Aatos Erkko Foundation to P.K. We also thank the Scribendi
proofreading team for language editing.
DISCLOSURE
X.W. and Y.Y.: The Department of Molecular and Human
Genetics at Baylor College of Medicine derives revenue from
molecular genetic testing offered at Baylor Genetics. The other
authors declare no conflicts of interest.
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
REFERENCES
1. Myllyharju J. Prolyl 4-hydroxylases, key enzymes in the synthesis of
collagens and regulation of the response to hypoxia, and their roles as
treatment targets. Ann Med. 2008;40:402–417.
2. Myllyharju J. Prolyl 4-hydroxylases, master regulators of the hypoxia
response. Acta Physiol (Oxf.). 2013;208:148–165.
3. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of
the HIF hydroxylase pathway. Mol Cell. 2008;30:393–402.
4. Guo H, Tong P, Liu Y, et al. Mutations of P4HA2 encoding prolyl 4-
hydroxylase 2 are associated with nonsyndromic high myopia. Genet
Med. 2015;17:300–306.
5. Rauch F, Fahiminiya S, Majewski J, et al. Cole-Carpenter syndrome is
caused by a heterozygous missense mutation in P4HB. Am J Hum Genet.
2015;96:425–431.
6. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes
a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.
Proc Natl Acad Sci USA 2006;103:654–659.
7. Percy MJ, Furlow PW, Beer PA, et al. A novel erythrocytosis-associated
PHD2 mutation suggests the location of a HIF binding groove. Blood.
2007;110:2193–2196.
8. Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital
erythrocytosis with paraganglioma. N Engl J Med. 2008;359:2685–2692.
9. Lorenzo FR, Huff C, Myllymäki M, et al. A genetic mechanism for Tibetan
high-altitude adaptation. Nat Genet. 2014;46:951–956.
10. Koivunen P, Tiainen P, Hyvärinen J, et al. An endoplasmic reticulum
transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on
hypoxia-inducible factor alpha. J Biol Chem. 2007;282:30544–30552.
11. Hyvärinen J, Parikka M, Sormunen R, et al. Deficiency of a
transmembrane prolyl 4-hydroxylase in the zebrafish leads to basement
membrane defects and compromised kidney function. J Biol Chem.
2010;285:42023–42032.
12. Leinonen H, Rossi M, Salo AM, et al. Lack of P4H-TM in mice results in
age-related retinal and renal alterations. Hum Mol Genet.
2016;25:3810–3823.
13. Kaasinen E, Rahikkala E, Koivunen P, et al. Clinical characterization,
genetic mapping and whole-genome sequence analysis of a novel
autosomal recessive intellectual disability syndrome. Eur J Med Genet.
2014;57:543–551.
14. Hautakangas M-R, Hinttala R, Rantala H, et al. Evaluating clinical
mitochondrial respiratory chain enzymes from biopsy specimens
presenting skewed probability distribution of activity data.
Mitochondrion. 2016;29:53–58.
15. Soemedi R, Cygan KJ, Rhine CL, et al. Pathogenic variants that alter
protein code often disrupt splicing. Nat Genet. 2017;49:848–855.
16. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel
putative proline 4-hydroxylase, modulates activity of hypoxia-inducible
transcription factors. Biochem Biophys Res Commun.
2002;296:343–349.
ARTICLE RAHIKKALA et al
2362 Volume 21 | Number 10 | October 2019 | GENETICS in MEDICINE
17. Laitala A, Aro E, Walkinshaw G, et al. Transmembrane prolyl 4-
hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production
and erythropoiesis. Blood. 2012;120:3336–3344.
18. Takeda K, Ho VC, Takeda H, et al. Placental but not heart defects are
associated with elevated hypoxia-inducible factor alpha levels in mice
lacking prolyl hydroxylase domain protein 2. Mol Cell Biol.
2006;26:8336–8346.
19. Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations
associated with severe non-syndromic sporadic intellectual disability: an
exome sequencing study. Lancet. 2012;380:1674–1682.
20. Lim ET, Würtz P, Havulinna AS, et al. Distribution and medical impact of
loss-of-function variants in the Finnish founder population. PLoS Genet.
2014;10:e1004494.
21. Norio R, Finnish Disease, Heritage I. characteristics, causes, background.
Hum Genet. 2003;112:441–456.
22. Boycott KM, Rath A, Chong JX, et al. International cooperation to enable
the diagnosis of all rare genetic diseases. Am J Hum Genet.
2017;100:695–705.
Open Access This article is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0 International
License, which permits any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. If you remix,
transform, or build upon this article or a part thereof, you must distribute your
contributions under the same license as the original. The images or other third
party material in this article are included in the article’s Creative Commons
license, unless indicated otherwise in a credit line to thematerial. Ifmaterial is not
included in the article’s Creative Commons license and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/.
© The Author(s) 2019
1PEDEGO Research Unit and Medical Research Centre Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland.
2Department of Clinical Genetics, Oulu University Hospital, Oulu, Finland. 3Biocenter Oulu, University of Oulu, Oulu, Finland.
4Faculty of Biochemistry and Molecular Medicine, Oulu Centre for Cell-Matrix Research, University of Oulu, Oulu, Finland.
5Department of Children and Adolescents, Division of Paediatric Neurology, Oulu University Hospital, Oulu, Finland. 6Kaiser Franz
Josef Hospital with G.v. Preyer Children’s Hospital, Department of Pediatrics, Vienna, Austria. 7Department of Clinical Genetics,
Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 8Neuromuscular Research Department, Medical
University of Vienna, Centre for Anatomy and Cell Biology, Vienna, Austria. 9Psychiatric & Neurodevelopmental Genetics Unit,
Massachusetts General Hospital, Boston, MA, USA. 10The Stanley Center for Psychiatric Research, The Broad Institute of MIT and
Harvard, Cambridge, MA, USA. 11Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. 12Texas
Children’s Hospital, Houston, TX, USA. 13Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. 14Northern
Finland Laboratory Centre NordLab and Medical Research Centre, Oulu University Hospital and University of Oulu, Oulu, Finland.
15Department of Pathology, Oulu University Hospital, Oulu, Finland. 16Analytic and Translational Genetics Unit, Department of
Medicine, Massachusetts General Hospital, Boston, MA, USA. 17Department of Neurology, Massachusetts General Hospital, Boston,
MA, USA. 18Department of Medical Genetics, Genome-Scale Biology Research Program, University of Helsinki and Haartman
Institute, Helsinki, Finland. 19Baylor Genetics, Houston, TX 77021, USA
RAHIKKALA et al ARTICLE
GENETICS in MEDICINE | Volume 21 | Number 10 | October 2019 2363
